Dopamine imbalance in Huntington's disease: A mechanism for the lack of behavioral flexibility

Frontiers in Neuroscience

Volumn , Issue 7 JUL, 2013, Pages

  Chen, Jane Y ^a   Wang, Elizabeth A ^a   Cepeda, Carlos ^a   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Behavioral inflexibility; Dopamine; Electrophysiology; Glutamate; Huntington's disease

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR;

BEHAVIOR CHANGE; BEHAVIOR DISORDER; BEHAVIORAL INFLEXIBILITY; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; HUMAN; HUNTINGTON CHOREA; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN INTERACTION; REVIEW;

EID: 84887918899     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2013.00114     Document Type: Review

References (214)

1. Afifi, A. K., Bahuth, N. B., Kaelber, W. W., Mikhael, E., and Nassar, S. (1974). The cortico-nigral fibre tract. An experimental Fink-Heimer study in cats. J. Anat. 118, 469-476.
2. Akopian, G., Crawford, C., Beal, M. F., Cappelletti, M., Jakowec, M. W., Petzinger, G. M., et al. (2008). Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia. J. Neurosci. 28, 9585-9597. doi: 10.1523/JNEUROSCI.5698-07.2008
3. Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375. doi: 10.1016/0166-2236(89)90074-X
4. Alpay, M., and Koroshetz, W. J. (2006). Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics 47, 70-72. doi: 10.1176/appi.psy.47.1.70
5. André, V. M., Cepeda, C., Fisher, Y. E., Huynh, M., Bardakjian, N., Singh, S., et al. (2011a). Differential electrophysiological changes in striatal output neurons in Huntington's disease. J. Neurosci. 31, 1170-1182. doi: 10.1523/JNEUROSCI.3539-10.2011
6. André, V. M., Fisher, Y. E., and Levine, M. S. (2011b). Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front. Syst. Neurosci. 5:46. doi: 10.3389/fnsys.2011.00046
7. Andrew, S. E., Goldberg, Y. P., Kremer, B., Telenius, H., Theilmann, J., Adam, S., et al. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 4, 398-403. doi: 10.1038/ng0893-398
8. Antonini, A., Leenders, K. L., Spiegel, R., Meier, D., Vontobel, P., Weigell-Weber, M., et al. (1996). Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119(Pt 6), 2085-2095. doi: 10.1093/brain/119.6.2085
9. Aosaki, T., Graybiel, A. M., and Kimura, M. (1994). Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys. Science 265, 412-415. doi: 10.1126/science.8023166
10. Aosaki, T., Miura, M., Suzuki, T., Nishimura, K., and Masuda, M. (2010). Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr. Gerontol. Int. 10(Suppl. 1), S148-S157. doi: 10.1111/j.1447-0594.2010.00588.x
11. Ariano, M. A., Aronin, N., Difiglia, M., Tagle, D. A., Sibley, D. R., Leavitt, B. R., et al. (2002). Striatal neurochemical changes in transgenic models of Huntington's disease. J. Neurosci. Res. 68, 716-729. doi: 10.1002/jnr.10272
12. Aron, A. R., Durston, S., Eagle, D. M., Logan, G. D., Stinear, C. M., and Stuphorn, V. (2007). Converging evidence for a fronto-basal-ganglia network for inhibitory control of action and cognition. J. Neurosci. 27, 11860-11864. doi: 10.1523/JNEUROSCI.3644-07.2007
13. Aron, A. R., and Poldrack, R. A. (2006). Cortical and subcortical contributions to Stop signal response inhibition: role of the subthalamic nucleus. J. Neurosci. 26, 2424-2433. doi: 10.1523/JNEUROSCI.4682-05.2006
14. Arvanov, V. L., Liang, X., Schwartz, J., Grossman, S., and Wang, R. Y. (1997). Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283, 226-234.
15. Backman, L., and Farde, L. (2001). Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. Scand. J. Psychol. 42, 287-296. doi: 10.1111/1467-9450.00238
16. Backman, L., Robins-Wahlin, T. B., Lundin, A., Ginovart, N., and Farde, L. (1997). Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 120(Pt 12), 2207-2217. doi: 10.1093/brain/120.12.2207
17. Bamford, N. S., Zhang, H., Schmitz, Y., Wu, N. P., Cepeda, C., Levine, M. S., et al. (2004). Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 42, 653-663. doi: 10.1016/S0896-6273(04)00265-X
18. Beglinger, L. J., Paulsen, J. S., Watson, D. B., Wang, C., Duff, K., Langbehn, D. R., et al. (2008). Obsessive and compulsive symptoms in prediagnosed Huntington's disease. J. Clin. Psychiatry 69, 1758-1765. doi: 10.4088/JCP.v69n1111
19. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455. doi: 10.1016/0022-510X(73)90175-5
20. Berridge, K. C., Aldridge, J. W., Houchard, K. R., and Zhuang, X. (2005). Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biol. 3:4. doi: 10.1186/1741-7007-3-4
21. Beste, C., Willemssen, R., Saft, C., and Falkenstein, M. (2010). Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects. Neuropsychologia 48, 366-373. doi: 10.1016/j.neuropsychologia.2009.09.023
22. Bibb, J. A., Yan, Z., Svenningsson, P., Snyder, G. L., Pieribone, V. A., Horiuchi, A., et al. (2000). Severe deficiences in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. U.S.A. 97, 6809-6814. doi: 10.1073/pnas.120166397
23. Bird, E. D. (1980). Chemical pathology of Huntington's disease. Annu. Rev. Pharmacol. Toxicol. 20, 533-551. doi: 10.1146/annurev.pa.20.040180.002533
24. Blanke, M. L., and Vandongen, A. M. J. (2009). "Activation mechanisms of the NMDA receptor," in Biology of the NMDA Receptor, ed A. M. J. Vandongen (Boca Raton, FL: CRC Press), Chapter 13.
25. Bolam, J. P., Hanley, J. J., Booth, P. A., and Bevan, M. D. (2000). Synaptic organisation of the basal ganglia. J. Anat. 196(Pt 4), 527-542. doi: 10.1046/j.1469-7580.2000.19640527.x
26. Bolam, J. P., Wainer, B. H., and Smith, A. D. (1984). Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. Neuroscience 12, 711-718. doi: 10.1016/0306-4522(84)90165-9
27. Bonelli, R. M., and Hofmann, P. (2007). A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin. Pharmacother. 8, 141-153. doi: 10.1517/14656566.8.2.141
28. Bonelli, R. M., and Wenning, G. K. (2006). Pharmacological management of Huntington's disease: an evidence-based review. Curr. Pharm. Des. 12, 2701-2720. doi: 10.2174/138161206777698693
29. Bonelli, R. M., Mayr, B. M., Niederwieser, G., Reisecker, F., and Kapfhammer, H. P. (2003). Ziprasidone in Huntington's disease: the first case reports. J. Psychopharmacol. 17, 459-460. doi: 10.1177/0269881103174009
30. Bozzi, Y., and Borrelli, E. (2006). Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it. Trends Neurosci. 29, 167-174. doi: 10.1016/j.tins.2006.01.002
31. Brandt, J., and Butters, N. (1986). The neuropsychology of Huntington's disease. Trends Neurosci. 9, 118-120. doi: 10.1016/0166-2236(86)90039-1
32. Brouillet, E., Conde, F., Beal, M. F., and Hantraye, P. (1999). Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59, 427-468. doi: 10.1016/S0301-0082(99)00005-2
33. Brusa, L., Orlacchio, A., Moschella, V., Iani, C., Bernardi, G., and Mercuri, N. B. (2009). Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov. Disord. 24, 126-129. doi: 10.1002/mds.22376
34. Calabresi, P., Centonze, D., Gubellini, P., and Bernardi, G. (1999). Activation of M1-like muscarinic receptors is required for the induction of corticostriatal LTP. Neuropharmacology 38, 323-326. doi: 10.1016/S0028-3908(98)00199-3
35. Calabresi, P., Pisani, A., Mercuri, N. B., and Bernardi, G. (1994). Post-receptor mechanisms underlying striatal long-term depression. J. Neurosci. 14, 4871-4881.
36. Callahan, J. W., and Abercrombie, E. D. (2011). In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and full-length (YAC128) transgenic mouse models of Huntington's disease. Front. Syst. Neurosci. 5:61. doi: 10.3389/fnsys.2011.00061
37. Canales, J. J. (2005). Stimulant-induced adaptations in neostriatal matrix and striosome systems: transiting from instrumental responding to habitual behavior in drug addiction. Neurobiol. Learn. Mem. 83, 93-103. doi: 10.1016/j.nlm.2004.10.006
38. Canales, J. J., and Graybiel, A. M. (2000). A measure of striatal function predicts motor stereotypy. Nat. Neurosci. 3, 377-383. doi: 10.1038/73949
39. Caraceni, T. A., Girotti, F., Giovannini, P., Pederzoli, M., and Parati, E. A. (1980). Effects of DA agonist in Huntington disease hyperkinesia. Ital. J. Neurol. Sci. 1, 155-161. doi: 10.1007/BF02335845
40. 2 receptor-containing striatal medium-sized spiny neurons. Eur. J. Neurosci. 27, 671-682. doi: 10.1111/j.1460-9568.2008.06038.x
41. Cepeda, C., Buchwald, N. A., and Levine, M. S. (1993). Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. U.S.A. 90, 9576-9580. doi: 10.1073/pnas.90.20.9576
42. Cepeda, C., Cummings, D. M., Andre, V. M., Holley, S. M., and Levine, M. S. (2010). Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro 2, e00033. doi: 10.1042/AN20090058
43. 2 dopamine receptor-deficient mice. J. Neurophysiol. 85, 659-670.
44. Cepeda, C., Hurst, R. S., Calvert, C. R., Hernandez-Echeagaray, E., Nguyen, O. K., Jocoy, E., et al. (2003). Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23, 961-969.
45. Cepeda, C., and Levine, M. S. (1998). Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20, 1-18. doi: 10.1159/000017294
46. Cha, J. H., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., et al. (1998). Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. U.S.A. 95, 6480-6485. doi: 10.1073/pnas.95.11.6480
47. Charvin, D., Roze, E., Perrin, V., Deyts, C., Betuing, S., Pages, C., et al. (2008). Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiol. Dis. 29, 22-29. doi: 10.1016/j.nbd.2007.07.028
48. 2 receptor stimulation. Proc. Natl. Acad. Sci. U.S.A. 102, 12218-12223. doi: 10.1073/pnas.0502698102
49. Cools, R., Ivry, R. B., and D'esposito, M. (2006). The human striatum is necessary for responding to changes in stimulus relevance. J. Cogn. Neurosci. 18, 1973-1983. doi: 10.1162/jocn.2006.18.12.1973
50. Cooper, S., and Dourish, C. (1990). Neurobiology of Stereotyped Behavior. Oxford: Clarendon Press.
51. Coyle, J. T., and Puttfarcken, P. (1993). Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695. doi: 10.1126/science.7901908
52. Crook, Z. R., and Housman, D. E. (2012). Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc. Natl. Acad. Sci. U.S.A. 109, 7487-7492. doi: 10.1073/pnas.1204542109
53. Cummings, D. M., Andre, V. M., Uzgil, B. O., Gee, S. M., Fisher, Y. E., Cepeda, C., et al. (2009). Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J. Neurosci. 29, 10371-10386. doi: 10.1523/JNEUROSCI.1592-09.2009
54. Cummings, D. M., Milnerwood, A. J., Dallerac, G. M., Waights, V., Brown, J. Y., Vatsavayai, S. C., et al. (2006). Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of huntington's disease. Hum. Mol. Genet. 15, 2856-2868. doi: 10.1093/hmg/ddl224
55. Cyr, M., Sotnikova, T. D., Gainetdinov, R. R., and Caron, M. G. (2006). Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J. 20, 2541-2543. doi: 10.1096/fj.06-6533fje
56. Dallerac, G. M., Vatsavayai, S. C., Cummings, D. M., Milnerwood, A. J., Peddie, C. J., Evans, K. A., et al. (2011). Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation. Neurodegener. Dis. 8, 230-239. doi: 10.1159/000322540
57. Dalley, J. W., Fryer, T. D., Brichard, L., Robinson, E. S., Theobald, D. E., Laane, K., et al. (2007). Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315, 1267-1270. doi: 10.1126/science.1137073
58. Dang, L. C., Donde, A., Madison, C., O'neil, J. P., and Jagust, W. J. (2012). Striatal dopamine influences the default mode network to affect shifting between object features. J. Cogn. Neurosci. 24, 1960-1970. doi: 10.1162/jocn_a_00252
59. 2 receptor subtypes in an in vitro model of cerebral hypoxia. Exp. Neurol. 176, 229-236. doi: 10.1006/exnr.2002.7926
60. De Yebenes, J. G., Landwehrmeyer, B., Squitieri, F., Reilmann, R., Rosser, A., Barker, R. A., et al. (2011). Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 10, 1049-1057. doi: 10.1016/S1474-4422(11)70233-2
61. Devan, B. D., McDonald, R. J., and White, N. M. (1999). Effects of medial and lateral caudate-putamen lesions on place- and cue-guided behaviors in the water maze: relation to thigmotaxis. Behav. Brain Res. 100, 5-14. doi: 10.1016/S0166-4328(98)00107-7
62. Dickinson, D., and Elvevag, B. (2009). Genes, cognition and brain through a COMT lens. Neuroscience 164, 72-87. doi: 10.1016/j.neuroscience.2009.05.014
63. Difiglia, M. (1990). Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13, 286-289. doi: 10.1016/0166-2236(90)90111-M
64. Ding, J. B., Guzman, J. N., Peterson, J. D., Goldberg, J. A., and Surmeier, D. J. (2010). Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 67, 294-307. doi: 10.1016/j.neuron.2010.06.017
65. Duff, K., Beglinger, L. J., O'rourke, M. E., Nopoulos, P., Paulson, H. L., and Paulsen, J. S. (2008). Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann. Clin. Psychiatry 20, 1-3. doi: 10.1080/10401230701844802
66. Fedoroff, J. P., Peyser, C., Franz, M. L., and Folstein, S. E. (1994). Sexual disorders in Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 6, 147-153.
67. Feng, J., Chi, P., Blanpied, T. A., Xu, Y., Magarinos, A. M., Ferreira, A., et al. (2002). Regulation of neurotransmitter release by synapsin III. J. Neurosci. 22, 4372-4380.
68. Fernagut, P. O., Diguet, E., Jaber, M., Bioulac, B., and Tison, F. (2002). Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. Eur. J. Neurosci. 15, 2053-2056. doi: 10.1046/j.1460-9568.2002.02047.x
69. Fletcher, E. J., and Macdonald, J. F. (1993). Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur. J. Pharmacol. 235, 291-295. doi: 10.1016/0014-2999(93)90148-B
70. Flores-Barrera, E., Vizcarra-Chacon, B. J., Tapia, D., Bargas, J., and Galarraga, E. (2010). Different corticostriatal integration in spiny projection neurons from direct and indirect pathways. Front. Syst. Neurosci. 4:15. doi: 10.3389/fnsys.2010.00015
71. Flores-Hernandez, J., Cepeda, C., Hernandez-Echeagaray, E., Calvert, C. R., Jokel, E. S., Fienberg, A. A., et al. (2002). Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J. Neurophysiol. 88, 3010-3020. doi: 10.1152/jn.00361.2002
72. Flores-Hernandez, J., Galarraga, E., and Bargas, J. (1997). Dopamine selects glutamatergic inputs to neostriatal neurons. Synapse 25, 185-195.
73. Frank, M. J., Seeberger, L. C., and O'reilly, R, C. (2004). By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 306, 1940-1943. doi: 10.1126/science.1102941
74. Frattola, L., Albizzati, M. G., Alemani, A., Bassi, S., Ferrarese, C., and Trabucchi, M. (1983). Acute treatment of Huntington's chorea with lisuride. J. Neurol. Sci. 59, 247-253. doi: 10.1016/0022-510X(83)90042-4
75. Frattola, L., Albiazzati, M. G., Spano, P. F., and Trabucchi, M. (1977). Treatment of Huntington's chorea with bromocriptine. Acta Neurol. Scand. 56, 37-45. doi: 10.1111/j.1600-0404.1977.tb01407.x
76. Freeman, W., and Morton, A. J. (2004). Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res. Bull. 63, 45-55. doi: 10.1016/j.brainresbull.2003.12.004
77. Galvan, L., André, V. M., Wang, E. A., Cepeda, C., and Levine, M. S. (2012). Functional differences between direct and indirect striatal output pathways in Huntington's disease. J. Huntingt. Dis. 1, 17-25.
78. Garrett, M. C., and Soares-Da-Silva, P. (1992). Increased cerebrospinal fluid dopamine and 3, 4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission. J. Neurochem. 58, 101-106. doi: 10.1111/j.1471-4159.1992.tb09283.x
79. Gerfen, C. R. (1984). The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 311, 461-464. doi: 10.1038/311461a0
80. Gerfen, C. R. (1992). The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15, 133-139. doi: 10.1016/0166-2236(92)90355-C
81. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432. doi: 10.1126/science.2147780
82. Gertler, T. S., Chan, C. S., and Surmeier, D. J. (2008). Dichotomous anatomical properties of adult striatal medium spiny neurons. J. Neurosci. 28, 10814-10824. doi: 10.1523/JNEUROSCI.2660-08.2008
83. Ginovart, N., Lundin, A., Farde, L., Halldin, C., Backman, L., Swahn, C. G., et al. (1997). PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 120(Pt 3), 503-514. doi: 10.1093/brain/120.3.503
84. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., and Caron, M. G. (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612. doi: 10.1038/379606a0
85. Gray, M., Shirasaki, D. I., Cepeda, C., Andre, V. M., Wilburn, B., Lu, X. H., et al. (2008). Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182-6195. doi: 10.1523/JNEUROSCI.0857-08.2008
86. Graybiel, A. M. (2000). The basal ganglia. Curr. Biol. 10, R509-R511. doi: 10.1016/S0960-9822(00)00593-5
87. Haber, S. N., and Nauta, W. J. (1983). Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry. Neuroscience 9, 245-260. doi: 10.1016/0306-4522(83)90291-9
88. Haskins, B. A., and Harrison, M. B. (2000). Huntington's disease. Curr. Treat. Options Neurol. 2, 243-262. doi: 10.1007/s11940-000-0007-0
89. Hastings, T. G. (2009). The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. J. Bioenerg. Biomembr. 41, 469-472. doi: 10.1007/s10863-009-9257-z
90. Hastings, T. G., Lewis, D. A., and Zigmond, M. J. (1996). Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 93, 1956-1961. doi: 10.1073/pnas.93.5.1956
91. Hedreen, J. C., and Folstein, S. E. (1995). Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 54, 105-120. doi: 10.1097/00005072-199501000-00013
92. Heinsen, H., Rub, U., Gangnus, D., Jungkunz, G., Bauer, M., Ulmar, G., et al. (1996). Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta. Neuropathol. 91, 161-168. doi: 10.1007/s004010050408
93. Hernandez-Lopez, S., Bargas, J., Surmeier, D. J., Reyes, A., and Galarraga, E. (1997). D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca2+ conductance. J. Neurosci. 17, 3334-3342.
94. Hickey, M. A., Reynolds, G. P., and Morton, A. J. (2002). The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 81, 46-59. doi: 10.1046/j.1471-4159.2002.00804.x
95. Hong, S. L., and Rebec, G. V. (2012). Biological sources of inflexibility in brain and behavior with aging and neurodegenerative diseases. Front. Syst. Neurosci. 6:77. doi: 10.3389/fnsys.2012.00077
96. Huntington Study Group. (2006). Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66, 366-372. doi: 10.1212/01.wnl.0000198586.85250.13
97. Hwang, W. J., and Yao, W. J. (2011). SPECT study of the nigrostriatal dopaminergic system in Huntington's disease. J. Neuroimaging 2, 192-196. doi: 10.1111/j.1552-6569.2011.00671.x
98. Ilyin, V. I., Whittemore, E. R., Guastella, J., Weber, E., and Woodward, R. M. (1996). Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol. Pharmacol. 50, 1541-1550.
99. Jahanshahi, A., Vlamings, R., Kaya, A. H., Lim, L. W., Janssen, M. L., Tan, S., et al. (2010). Hyperdopaminergic status in experimental Huntington disease. J. Neuropathol. Exp. Neurol. 69, 910-917. doi: 10.1097/NEN.0b013e3181ee005d
100. Jakel, R. J., and Maragos, W. F. (2000). Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 23, 239-245. doi: 10.1016/S0166-2236(00)01568-X
101. Jhanjee, A., Anand, K. S., and Bajaj, B. K. (2011). Hypersexual features in Huntington's disease. Singapore Med. J. 52, e131-e133.
102. Jimenez-Castellanos, J., and Graybiel, A. M. (1989). Compartmental origins of striatal efferent projections in the cat. Neuroscience 32, 297-321. doi: 10.1016/0306-4522(89)90080-8
103. Johnson, M. A., Rajan, V., Miller, C. E., and Wightman, R. M. (2006). Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem. 97, 737-746. doi: 10.1111/j.1471-4159.2006.03762.x
104. Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M., and Caron, M. G. (1998). Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. U.S.A. 95, 4029-4034. doi: 10.1073/pnas.95.7.4029
105. Joshi, P. R., Wu, N. P., Andre, V. M., Cummings, D. M., Cepeda, C., Joyce, J. A., et al. (2009). Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 29, 2414-2427. doi: 10.1523/JNEUROSCI.5687-08.2009
106. Joyce, J. N., Lexow, N., Bird, E., and Winokur, A. (1988). Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 2, 546-557. doi: 10.1002/syn.890020511
107. Kalivas, P. W., Duffy, P., and Barrow, J. (1989). Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J. Pharmacol. Exp. Ther. 251, 378-387.
108. Kemp, J. M., and Powell, T. P. (1971). The termination of fibres from the cerebral cortex and thalamus upon dendritic spines in the caudate nucleus: a study with the Golgi method. Philos. Trans. R. Soc. Lond. B Biol. Sci. 262, 429-439. doi: 10.1098/rstb.1971.0105
109. Kerr, J. N., and Wickens, J. R. (2001). Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J. Neurophysiol. 85, 117-124.
110. Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Kanki, R., et al. (2002). Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J. Neurosci. Res. 70, 274-282. doi: 10.1002/jnr.10426
111. Kile, B. M., Guillot, T. S., Venton, B. J., Wetsel, W. C., Augustine, G. J., and Wightman, R. M. (2010). Synapsins differentially control dopamine and serotonin release. J. Neurosci. 30, 9762-9770. doi: 10.1523/JNEUROSCI.2071-09.2010
112. Kish, S. J., Shannak, K., and Hornykiewicz, O. (1987). Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann. Neurol. 22, 386-389. doi: 10.1002/ana.410220318
113. Kita, H., and Kitai, S. T. (1988). Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Res. 447, 346-352. doi: 10.1016/0006-8993(88)91138-9
114. Kiyatkin, E. A., and Rebec, G. V. (1996). Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats. J. Neurophysiol. 75, 142-153.
115. Klapstein, G. J., Fisher, R. S., Zanjani, H., Cepeda, C., Jokel, E. S., Chesselet, M. F., et al. (2001). Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 86, 2667-2677.
116. Klawans, H. C., Paulson, G. W., and Barbeau, A. (1970). Predictive test for Huntington's chorea. Lancet 2, 1185-1186. doi: 10.1016/S0140-6736(70)90367-3
117. Kornhuber, J., Kim, J. S., Kornhuber, M. E., and Kornhuber, H. H. (1984). The cortico-nigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat. Brain Res. 322, 124-126. doi: 10.1016/0006-8993(84)91189-2
118. Kreitzer, A. C., and Malenka, R. C. (2005). Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J. Neurosci. 25, 10537-10545. doi: 10.1523/JNEUROSCI.2959-05.2005
119. Kreitzer, A. C., and Malenka, R. C. (2007). Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445, 643-647. doi: 10.1038/nature05506
120. Kremer, H. P., Roos, R. A., Dingjan, G., Marani, E., and Bots, G. T. (1990). Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J. Neuropathol. Exp. Neurol. 49, 371-382. doi: 10.1097/00005072-199007000-00002
121. Kung, V. W., Hassam, R., Morton, A. J., and Jones, S. (2007). Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience 146, 1571-1580. doi: 10.1016/j.neuroscience.2007.03.036
122. Laughlin, R. E., Grant, T. L., Williams, R. W., and Jentsch, J. D. (2011). Genetic dissection of behavioral flexibility: reversal learning in mice. Biol. Psychiatry 69, 1109-1116. doi: 10.1016/j.biopsych.2011.01.014
123. Lawrence, A. D., Sahakian, B. J., Hodges, J. R., Rosser, A. E., Lange, K. W., and Robbins, T. W. (1996). Executive and mnemonic functions in early Huntington's disease. Brain 119(Pt 5), 1633-1645. doi: 10.1093/brain/119.5.1633
124. Lee, B., London, E. D., Poldrack, R. A., Farahi, J., Nacca, A., Monterosso, J. R., et al. (2009). Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J. Neurosci. 29, 14734-14740. doi: 10.1523/JNEUROSCI.3765-09.2009
125. Lee, F. J., Xue, S., Pei, L., Vukusic, B., Chery, N., Wang, Y., et al. (2002). Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111, 219-230. doi: 10.1016/S0092-8674(02)00962-5
126. Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., and Chesselet, M. F. (2004). Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci. 27, 691-697. doi: 10.1016/j.tins.2004.08.008
127. Levine, M. S., Li, Z., Cepeda, C., Cromwell, H. C., and Altemus, K. L. (1996). Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse 24, 65-78. doi: 10.1002/syn.890240102
128. Lobo, M. K., Yeh, C., and Yang, X. W. (2008). Pivotal role of early B-cell factor 1 in development of striatonigral medium spiny neurons in the matrix compartment. J. Neurosci. Res. 86, 2134-2146. doi: 10.1002/jnr.21666
129. Maejima, T., Ohno-Shosaku, T., and Kano, M. (2001). Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neurosci. Res. 40, 205-210. doi: 10.1016/S0168-0102(01)00241-3
130. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506. doi: 10.1016/S0092-8674(00)81369-0
131. Maurice, N., Deniau, J. M., Glowinski, J., and Thierry, A. M. (1999). Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the cortico-nigral circuits. J. Neurosci. 19, 4674-4681.
132. McLaughlin, B. A., Nelson, D., Erecinska, M., and Chesselet, M. F. (1998). Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 70, 2406-2415. doi: 10.1046/j.1471-4159.1998.70062406.x
133. Meltzer, L. T., Christoffersen, C. L., and Serpa, K. A. (1997). Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci. Biobehav. Rev. 21, 511-518. doi: 10.1016/S0149-7634(96)00030-9
134. Menalled, L. B. (2005). Knock-in mouse models of Huntington's disease. NeuroRx 2, 465-470. doi: 10.1602/neurorx.2.3.465
135. Mestre, T. A., and Ferreira, J. J. (2012). An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat. Disord. 18, 316-320. doi: 10.1016/j.parkreldis.2011.10.021
136. Miller, B. R., Dorner, J. L., Shou, M., Sari, Y., Barton, S. J., Sengelaub, D. R., et al. (2008). Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153, 329-337. doi: 10.1016/j.neuroscience.2008.02.004
137. Mintz, I., Hammond, C., Guibert, B., and Leviel, V. (1986). Stimulation of the subthalamic nucleus enhances the release of dopamine in the rat substantia nigra. Brain Res. 376, 406-408. doi: 10.1016/0006-8993(86)90209-X
138. Mizumori, S. J. Y., Ragozzino, K. E., and Cooper, B. G. (2000). Location and head direction representation in the dorsal striatum of rats. Psychobiology 28, 441-462.
139. Mochel, F., Durant, B., Durr, A., and Schiffmann, R. (2011). Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice. PLoS ONE 6:e18336. doi: 10.1371/journal.pone.0018336
140. Murase, S., Grenhoff, J., Chouvet, G., Gonon, F. G., and Svensson, T. H. (1993). Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci. Lett. 157, 53-56. doi: 10.1016/0304-3940(93)90641-W
141. Naito, A., and Kita, H. (1994). The cortico-nigral projection in the rat: an anterograde tracing study with biotinylated dextran amine. Brain Res. 637, 317-322. doi: 10.1016/0006-8993(94)91252-1
142. Nieoullon, A., Cheramy, A., and Glowinski, J. (1978). Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat. Brain Res. 145, 69-83. doi: 10.1016/0006-8993(78)90797-7
143. Ortiz, A. N., Kurth, B. J., Osterhaus, G. L., and Johnson, M. A. (2010). Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J. Neurochem. 112, 755-761. doi: 10.1111/j.1471-4159.2009.06501.x
144. Ortiz, A. N., Osterhaus, G. L., Lauderdale, K., Mahoney, L., Fowler, S. C., Von Horsten, S., et al. (2012). Motor function and dopamine release measurements in transgenic Huntington's disease model rats. Brain Res. 1450, 148-156. doi: 10.1016/j.brainres.2012.02.042
145. Owen, A. M., Roberts, A. C., Hodges, J. R., Summers, B. A., Polkey, C. E., and Robbins, T. W. (1993). Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain 116(Pt 5), 1159-1175. doi: 10.1093/brain/116.5.1159
146. Paoletti, P., Vila, I., Rife, M., Lizcano, J. M., Alberch, J., and Gines, S. (2008). Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J. Neurosci. 28, 10090-10101. doi: 10.1523/JNEUROSCI.3237-08.2008
147. Partridge, J. G., Tang, K. C., and Lovinger, D. M. (2000). Regional and postnatal heterogeneity of activity-dependent long-term changes in synaptic efficacy in the dorsal striatum. J. Neurophysiol. 84, 1422-1429.
148. Patel, S., Rademacher, D. J., and Hillard, C. J. (2003). Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J. Pharmacol. Exp. Ther. 306, 880-888. doi: 10.1124/jpet.103.054270
149. Pavese, N., Andrews, T. C., Brooks, D. J., Ho, A. K., Rosser, A. E., Barker, R. A., et al. (2003). Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126, 1127-1135. doi: 10.1093/brain/awg119
150. Peinemann, A., Schuller, S., Pohl, C., Jahn, T., Weindl, A., and Kassubek, J. (2005). Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J. Neurol. Sci. 239, 11-19. doi: 10.1016/j.jns.2005.07.007
151. Petersen, A. A., Larsen, K. E., Behr, G. G., Romero, N., Przedborski, S., Brundin, P., et al. (2001). Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death. Brain Res. Bull. 56, 331-335. doi: 10.1016/S0361-9230(01)00580-9
152. Petersen, A., Chase, K., Puschban, Z., Difiglia, M., Brundin, P., and Aronin, N. (2002a). Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp. Neurol. 175, 297-300. doi: 10.1006/exnr.2002.7885
153. Petersen, A., Puschban, Z., Lotharius, J., Nicniocaill, B., Wiekop, P., O'connor, W. T., et al. (2002b). Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 11, 134-146. doi: 10.1006/nbdi.2002.0534
154. Petersen, A., Gil, J., Maat-Schieman, M. L., Bjorkqvist, M., Tanila, H., Araujo, I. M., et al. (2005). Orexin loss in Huntington's disease. Hum. Mol. Genet. 14, 39-47. doi: 10.1093/hmg/ddi004
155. Picconi, B., Passino, E., Sgobio, C., Bonsi, P., Barone, I., Ghiglieri, V., et al. (2006). Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol. Dis. 22, 143-152. doi: 10.1016/j.nbd.2005.10.009
156. Pierce, R. C., and Rebec, G. V. (1995). Iontophoresis in the neostriatum of awake, unrestrained rats: differential effects of dopamine, glutamate and ascorbate on motor- and nonmotor-related neurons. Neuroscience 67, 313-324. doi: 10.1016/0306-4522(95)00012-8
157. Pifl, C., Pichler, L., Kobinger, W., and Hornykiewicz, O. (1988). The dopamine autoreceptor agonist, B-HT 920, preferentially reduces brain dopamine release in vivo: biochemical indices of brain dopamine, noradrenaline and serotonin in ventriculocisternal perfusates in the cat. Eur. J. Pharmacol. 153, 33-44. doi: 10.1016/0014-2999(88)90585-7
158. Pisa, M., and Cyr, J. (1990). Regionally selective roles of the rat's striatum in modality-specific discrimination learning and forelimb reaching. Behav. Brain Res. 37, 281-292. doi: 10.1016/0166-4328(90)90140-A
159. Pouladi, M. A., Stanek, L. M., Xie, Y., Franciosi, S., Southwell, A. L., Deng, Y., et al. (2012). Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet. 21, 2219-2232. doi: 10.1093/hmg/dds037
160. Racette, B. A., and Perlmutter, J. S. (1998). Levodopa responsive parkinsonism in an adult with Huntington's disease. J. Neurol. Neurosurg. Psychiatr. 65, 577-579. doi: 10.1136/jnnp.65.4.577
161. Ragozzino, M. E. (2007). The contribution of the medial prefrontal cortex, orbitofrontal cortex, and dorsomedial striatum to behavioral flexibility. Ann. N.Y. Acad. Sci. 1121, 355-375. doi: 10.1196/annals.1401.013
162. Raymond, L. A., André, V. M., Cepeda, C., Gladding, C. M., Milnerwood, A. J., and Levine, M. S. (2011). Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 15, 252-273. doi: 10.1016/j.neuroscience.2011.08.052
163. Reading, P. J., Dunnett, S. B., and Robbins, T. W. (1991). Dissociable roles of the ventral, medial and lateral striatum on the acquisition and performance of a complex visual stimulus-response habit. Behav. Brain Res. 45, 147-161. doi: 10.1016/S0166-4328(05)80080-4
164. Richfield, E. K., O'brien, C. F., Eskin, T., and Shoulson, I. (1991). Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett. 132, 121-126. doi: 10.1016/0304-3940(91)90448-3
165. Ridley, R. M. (1994). The psychology of perserverative and stereotyped behaviour. Prog. Neurobiol. 44, 221-231. doi: 10.1016/0301-0082(94)90039-6
166. Rosas, H. D., Tuch, D. S., Hevelone, N. D., Zaleta, A. K., Vangel, M., Hersch, S. M., et al. (2006). Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord. 21, 1317-1325. doi: 10.1002/mds.20979
167. Rosenblatt, A. (2007). Neuropsychiatry of Huntington's disease. Dialogues Clin. Neurosci. 9, 191-197.
168. Saka, E., Goodrich, C., Harlan, P., Madras, B. K., and Graybiel, A. M. (2004). Repetitive behaviors in monkeys are linked to specific striatal activation patterns. J. Neurosci. 24, 7557-7565. doi: 10.1523/JNEUROSCI.1072-04.2004
169. Sandstrom, M. I., Steffes-Loydahl, S., Jayaprakash, N., Wolfram-Aduan, A., and Dunbar, G. L. (2010). "Early dysfunction of neural transmission and cognitive processing in Huntington's disease," in Huntington's Disease - Core Concepts and Current Advances, ed N. Tunali (New York, NY: InTech), 201-232.
170. 1-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44, 110-119. doi: 10.1002/ana.410440117
171. 2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13, 1080-1087.
172. Seneca, S., Fagnart, D., Keymolen, K., Lissens, W., Hasaerts, D., Debulpaep, S., et al. (2004). Early onset Huntington disease: a neuronal degeneration syndrome. Eur. J. Pediatr. 163, 717-721. doi: 10.1007/s00431-004-1537-3
173. Sesack, S. R., and Carr, D. B. (2002). Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol. Behav. 77, 513-517. doi: 10.1016/S0031-9384(02)00931-9
174. Shen, S., Pu, J., Lang, B., and McCaig, C. D. (2011). A zinc finger protein Zfp521 directs neural differentiation and beyond. Stem Cell Res. Ther. 2, 20. doi: 10.1186/scrt61
175. Singla, S., Kreitzer, A. C., and Malenka, R. C. (2007). Mechanisms for synapse specificity during striatal long-term depression. J. Neurosci. 27, 5260-5264. doi: 10.1523/JNEUROSCI.0018-07.2007
176. Slow, E. J., Van Raamsdonk, J., Rogers, D., Coleman, S. H., Graham, R. K., Deng, Y., et al. (2003). Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12, 1555-1567. doi: 10.1093/hmg/ddg169
177. Smith, R., Musleh, W., Akopian, G., Buckwalter, G., and Walsh, J. P. (2001). Regional differences in the expression of corticostriatal synaptic plasticity. Neuroscience 106, 95-101. doi: 10.1016/S0306-4522(01)00260-3
178. Smith, Y., Raju, D. V., Pare, J. F., and Sidibe, M. (2004). The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 27, 520-527. doi: 10.1016/j.tins.2004.07.004
179. Spampanato, J., Gu, X., Yang, X. W., and Mody, I. (2008). Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 157, 606-620. doi: 10.1016/j.neuroscience.2008.09.020
180. 2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Res. Mol. Brain Res. 102, 118-128. doi: 10.1016/S0169-328X(02)00216-4
181. Spencer, J. P., and Murphy, K. P. (2000). Bi-directional changes in synaptic plasticity induced at corticostriatal synapses in vitro. Exp. Brain Res. 135, 497-503. doi: 10.1007/s002210000523
182. Spokes, E. G. (1980). Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 103, 179-210. doi: 10.1093/brain/103.1.179
183. Squitieri, F., Cannella, M., Piorcellini, A., Brusa, L., Simonelli, M., and Ruggieri, S. (2001). Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol. Behav. Neurol. 14, 69-72.
184. Stack, E. C., Dedeoglu, A., Smith, K. M., Cormier, K., Kubilus, J. K., Bogdanov, M., et al. (2007). Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 27, 12908-12915. doi: 10.1523/JNEUROSCI.4318-07.2007
185. Stalnaker, T. A., Takahashi, Y., Roesch, M. R., and Schoenbaum, G. (2009). Neural substrates of cognitive inflexibility after chronic cocaine exposure. Neuropharmacology 56(Suppl. 1), 63-72. doi: 10.1016/j.neuropharm.2008.07.019
186. 2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience 88, 795-810. doi: 10.1016/S0306-4522(98)00241-3
187. Stout, J. C., Rodawalt, W. C., and Siemers, E. R. (2001). Risky decision making in Huntington's disease. J. Int. Neuropsychol. Soc. 7, 92-101. doi: 10.1017/S1355617701711095
188. Suzuki, M., Desmond, T. J., Albin, R. L., and Frey, K. A. (2001). Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse 41, 329-336. doi: 10.1002/syn.1089
189. Tang, T. S., Chen, X., Liu, J., and Bezprozvanny, I. (2007). Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 27, 7899-7910. doi: 10.1523/JNEUROSCI.1396-07.2007
190. Tedroff, J., Ekesbo, A., Sonesson, C., Waters, N., and Carlsson, A. (1999). Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology 53, 1605-1606. doi: 10.1212/WNL.53.7.1605
191. Tepper, J. M., Wilson, C. J., and Koos, T. (2008). Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res. Rev. 58, 272-281. doi: 10.1016/j.brainresrev.2007.10.008
192. The Huntington's Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983. doi: 10.1016/0092-8674(93)90585-E
193. Tobin, A. J., and Signer, E. R. (2000). Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 10, 531-536. doi: 10.1016/S0962-8924(00)01853-5
194. 1 muscarinic receptor blockade and nicotinic receptor blockade in the dorsomedial striatum on response reversal learning. Behav. Brain Res. 154, 245-253. doi: 10.1016/j.bbr.2004.02.011
195. 2 receptor binding in pre-clinical Huntington's disease. Eur. J. Neurol. 16, 226-231. doi: 10.1111/j.1468-1331.2008.02390.x
196. Venuto, C. S., McGarry, A., Ma, Q., and Kieburtz, K. (2012). Pharmacologic approaches to the treatment of Huntington's disease. Mov. Disord. 27, 31-41. doi: 10.1002/mds.23953
197. 1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 10, 376-384. doi: 10.1038/nn1846
198. Vincent, S., Hokfelt, T., Christensson, I., and Terenius, L. (1982). Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur. J. Pharmacol. 85, 251-252. doi: 10.1016/0014-2999(82)90477-0
199. Von Horsten, S., Schmitt, I., Nguyen, H. P., Holzmann, C., Schmidt, T., Walther, T., et al. (2003). Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 12, 617-624. doi: 10.1093/hmg/ddg075
200. Vonsattel, J. P., and Difiglia, M. (1998). Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369-384. doi: 10.1097/00005072-199805000-00001
201. Wang, E., Cepeda, C., and Levine, M. S. (2012). Cognitive deficits in Huntington's disease: insights from animal models. Curr. Trans. Geriatr. Gerontol. Rep. 1, 29-38. doi: 10.1007/s13670-011-0005-y
202. Wang, H., Chen, X., Li, Y., Tang, T. S., and Bezprozvanny, I. (2010). Tetrabenazine is neuroprotective in Huntington's disease mice. Mol. Neurodegener. 5, 18. doi: 10.1186/1750-1326-5-18
203. (1) dopamine receptors potentiate nmda-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb. Cortex 11, 452-462. doi: 10.1093/cercor/11.5.452
204. Wang, S. H., and Morris, R. G. (2010). Hippocampal-neocortical interactions in memory formation, consolidation, and reconsolidation. Annu. Rev. Psychol. 61, 49-79, C41-C44.
205. Wang, Z., Kai, L., Day, M., Ronesi, J., Yin, H. H., Ding, J., et al. (2006). Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 50, 443-452. doi: 10.1016/j.neuron.2006.04.010
206. Waszczak, B. L., Martin, L. P., Finlay, H. E., Zahr, N., and Stellar, J. R. (2002). Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia. J. Pharmacol. Exp. Ther. 300, 850-861. doi: 10.1124/jpet.300.3.850
207. 2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 40, 49-54. doi: 10.1002/ana.410400110
208. Wersinger, C., Chen, J., and Sidhu, A. (2004). Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation. Mol. Cell. Neurosci. 25, 124-137. doi: 10.1016/j.mcn.2003.10.002
209. Whishaw, I. Q., Mittleman, G., Bunch, S. T., and Dunnett, S. B. (1987). Impairments in the acquisition, retention and selection of spatial navigation strategies after medial caudate-putamen lesions in rats. Behav. Brain Res. 24, 125-138. doi: 10.1016/0166-4328(87)90250-6
210. 1 receptor function in working memory. Neuroscience 139, 263-276. doi: 10.1016/j.neuroscience.2005.09.028
211. Wu, J., Tang, T., and Bezprozvanny, I. (2006). Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci. Lett. 407, 219-223. doi: 10.1016/j.neulet.2006.08.036
212. Zeron, M. M., Fernandes, H. B., Krebs, C., Shehadeh, J., Wellington, C. L., Leavitt, B. R., et al. (2004). Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 25, 469-479. doi: 10.1016/j.mcn.2003.11.014
213. Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., et al. (2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860. doi: 10.1016/S0896-6273(02)00615-3
214. Zhou, F. M., Wilson, C. J., and Dani, J. A. (2002). Cholinergic interneuron characteristics and nicotinic properties in the striatum. J. Neurobiol. 53, 590-605. doi: 10.1002/neu.10150